`_______________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`SAMSUNG BIOEPIS CO., LTD.
`Petitioner,
`
`v.
`REGENERON PHARMACEUTICALS, INC.
`Patent Owner.
`
`Patent No. 11,253,572
`
`_______________
`Inter Partes Review No. IPR2023-00884
`____________________________________________________________
`
`DECLARATION OF KIRA A. DAVIS IN SUPPORT OF
`MOTION FOR ADMISSION PRO HAC VICE
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 1
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`I, Kira A. Davis, declare as follows:
`
`1.
`
`I am an attorney licensed to practice law in the states of New York
`
`and California and am admitted to practice before the United States Court of
`
`Appeals for the Federal Circuit. I am also admitted to practice before the United
`
`States Court of Appeals for the Second Circuit, the United States Court of Appeals
`
`for the Sixth Circuit, and the United States District Courts for the Southern District
`
`of New York, the Eastern District of New York, the Northern District of
`
`California, and the Central District of California.
`
`2.
`
`I am a member in good standing in all jurisdictions where I have been
`
`admitted to practice.
`
`3.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`4.
`
`I have never had an application denied for admission before any court
`
`or administrative body.
`
`5.
`
`I have never had any sanctions or contempt citations imposed by any
`
`court or administrative body.
`
`6.
`
`I have read and agree to comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in 37 C.F.R. part 42.
`
`7.
`
`I affirm my agreement before the USPTO to be subject to the USPTO
`
`Rules of Professional Conduct 37 C.F.R. §§ 11.101 et seq. and disciplinary
`
`
`
`
`1
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 2
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`jurisdiction under 37 C.F.R. § 11.19(a).
`
`8.
`
`I have applied to appear pro hac vice in the following proceedings
`
`before the USPTO in the last three (3) years:
`
`a. Celltrion Inc. v. Regeneron Pharmaceuticals Inc., IPR2023-00462
`
`(pro hac vice granted).
`
`b. Samsung Bioepis Co., LTD v. Regeneron Pharmaceuticals Inc.,
`
`IPR2023-00739 (pro hac vice pending).
`
`9.
`
`I have been a partner at the law firm of Morrison & Foerster LLP
`
`since I joined the firm on January 1, 2023. I was previously a partner at the law
`
`firm of Durie Tangri LLP, from July 1, 2020 through December 31, 2022. Prior to
`
`that I was employed at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison
`
`LLP. I have worked on patent litigation matters, and particularly, patent litigation
`
`matters relating to biotechnology, for approximately 12 years. Over my twelve
`
`years working on patent litigation matters, I have handled many patent cases
`
`relating to methods of treatment using biologic therapeutics, including fusion
`
`proteins and antibodies.
`
`10.
`
`I am familiar with the subject matter at issue in this proceeding. I
`
`have been engaged by the Patent Owner to represent the Patent Owner before the
`
`Board in this proceeding. I have undertaken the study of inter alia the ’572 Patent,
`
`the Petition for Inter Partes Review, and the art cited in the Petition. I am also
`
`
`
`
`2
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 3
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`
`
`IPR2023-00884
`
`familiar with the co-pending litigations identified by the Petitioner in the Petition
`
`for Inter Partes Review, Paper 2 at 6. I have represented Patent Owner in patent
`
`matters relating to Eylea® since September 2022. I have acquired a substantial
`
`understanding of the underlying legal and technological issues at stake in these
`
`proceedings.
`
`
`
`
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements are made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code and that such willful false
`
`statements may jeopardize the validity of U.S. Patent No. 11,253,572.
`
`
`
`Dated: December 20, 2023
`
`
`
`
`
`By: /Kira A. Davis/
`Kira A. Davis
`MORRISON & FOERSTER LLP
`707 Wilshire Boulevard, Suite 6000
`Los Angeles, CA 90017
`Tel: (213) 892-5654
`
`
`
`
`3
`
`Regeneron Pharmaceuticals, Inc. Exhibit 2060 Page 4
`Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc. IPR2023-00884
`
`